- Home
- WBS vs VTRS Comparison
WBS vs VTRS Comparison
Compare WBS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBS
- VTRS
- Stock Information
- Founded
- WBS 1935
- VTRS 1961
- Country
- WBS United States
- VTRS United States
- Employees
- WBS N/A
- VTRS N/A
- Industry
- WBS Major Banks
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- WBS Finance
- VTRS Health Care
- Exchange
- WBS Nasdaq
- VTRS Nasdaq
- Market Cap
- WBS 9.1B
- VTRS 9.0B
- IPO Year
- WBS N/A
- VTRS N/A
- Fundamental
- Price
- WBS $49.78
- VTRS $8.77
- Analyst Decision
- WBS Buy
- VTRS Hold
- Analyst Count
- WBS 12
- VTRS 4
- Target Price
- WBS $63.08
- VTRS $10.50
- AVG Volume (30 Days)
- WBS 1.3M
- VTRS 13.4M
- Earning Date
- WBS 06-26-2025
- VTRS 05-08-2025
- Dividend Yield
- WBS 3.22%
- VTRS 5.41%
- EPS Growth
- WBS N/A
- VTRS N/A
- EPS
- WBS 4.44
- VTRS N/A
- Revenue
- WBS $2,372,492,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- WBS $10.53
- VTRS N/A
- Revenue Next Year
- WBS $5.54
- VTRS $1.20
- P/E Ratio
- WBS $11.21
- VTRS N/A
- Revenue Growth
- WBS N/A
- VTRS N/A
- 52 Week Low
- WBS $39.34
- VTRS $6.85
- 52 Week High
- WBS $63.99
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- WBS 56.96
- VTRS 57.48
- Support Level
- WBS $48.37
- VTRS $8.47
- Resistance Level
- WBS $50.37
- VTRS $9.57
- Average True Range (ATR)
- WBS 1.41
- VTRS 0.30
- MACD
- WBS 0.56
- VTRS 0.15
- Stochastic Oscillator
- WBS 87.76
- VTRS 59.39
About WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.